BOTHELL, WA and VANCOUVER, BC, Sept. 1, 2011 /CNW/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that senior
management will present at the following investor conferences:
Scott Cormack, OncoGenex' President and Chief Executive Officer, will
provide a corporate presentation at the Stifel Nicolaus Healthcare Conference on Wednesday, September 7 at 8:00 a.m. ET at the Four Seasons
Hotel in Boston.
Scott Cormack will provide a corporate presentation at the Rodman &
Renshaw 13th Annual Healthcare Conference on Monday, September 12 at
3:15 p.m. ET at the Waldorf-Astoria Hotel in New York City.
The live audio webcasts can be accessed through the Investor Relations
page of the OncoGenex website at www.oncogenex.com. Webcast replays will be available approximately one hour after a live
webcast concludes and will be archived for 90 days.
About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new cancer therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries
Ltd. (NASDAQ: TEVA) have entered a global collaboration and license
agreement to develop and commercialize OncoGenex' lead drug candidate,
custirsen. Custirsen is currently in Phase 3 clinical development as a
treatment in men with metastatic castrate-resistant prostate cancer.
The companies plan to begin Phase 3 development of custirsen in
first-line treatment of advanced, unresectable non-small cell lung
cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and
OGX-225 are currently in pre-clinical development.
OncoGenex's Forward Looking Statements
This press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, including, but not limited to,
statements concerning our anticipated product development activities
and the timing of these activities. All statements other than
statements of historical fact are statements that could be deemed
forward-looking statements. These statements are based on management's
current expectations and beliefs and are subject to a number of risks,
uncertainties and assumptions that could cause actual results to differ
materially from those described in the forward-looking statements. Such
forward-looking statements are subject to risks and uncertainties,
including, among others, uncertainties regarding our future operating
results, the risk that our product candidates will not obtain the
requisite regulatory approvals to commercialize or that the future
sales of our product candidates may be less than expected, and the risk
factors set forth in the Company's filings with the Securities and
Exchange Commission, including the Company's Annual Report on Form 10-K
for fiscal year 2010 and the Company's Quarterly Report on Form 10-Q
for the quarter ended June 30, 2011. The Company undertakes no
obligation to update the forward-looking statements contained herein or
to reflect events or circumstances occurring after the date hereof,
other than as may be required by applicable law.
SOURCE OncoGenex Pharmaceuticals, Inc.
For further information:
Director, Investor Relations